Marshwinds Advisory’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
$591K Hold
7,100
0.32% 74
2018
Q3
$766K Hold
7,100
0.35% 73
2018
Q2
$781K Hold
7,100
0.37% 70
2018
Q1
$712K Hold
7,100
0.34% 75
2017
Q4
$699K Hold
7,100
0.32% 78
2017
Q3
$665K Hold
7,100
0.31% 75
2017
Q2
$789K Sell
7,100
-100
-1% -$10.6K 0.37% 73
2017
Q1
$707K Hold
7,200
0.33% 76
2016
Q4
$662K Hold
7,200
0.32% 80
2016
Q3
$609K Hold
7,200
0.3% 82
2016
Q2
$586K Hold
7,200
0.29% 83
2016
Q1
$514K Sell
7,200
-150
-2% -$10.1K 0.26% 86
2015
Q4
$523K Hold
7,350
0.27% 88
2015
Q3
$452K Hold
7,350
0.24% 95
2015
Q2
$533K Sell
7,350
-250
-3% -$18.5K 0.27% 88
2015
Q1
$584K Hold
7,600
0.28% 89
2014
Q4
$510K Hold
7,600
0.24% 98
2014
Q3
$461K Buy
7,600
+50
+0.7% +$3.08K 0.23% 99
2014
Q2
$443K Hold
7,550
0.21% 103
2014
Q1
$437K Buy
7,550
+400
+6% +$21.4K 0.22% 99
2013
Q4
$383K Sell
7,150
-2,650
-27% -$157K 0.2% 102
2013
Q3
$606K Hold
9,800
0.35% 84
2013
Q2
$594K Buy
+9,800
New +$584K 0.35% 83

Other funds holding DGX

Marshwinds Advisory's DGX Position: Q4 2018 in Review

Marshwinds Advisory held its Quest Diagnostics (DGX) position steady in Q4 2018 at 7,100 shares worth $591K. The position accounts for 0.32% of the portfolio, ranked #74.

Marshwinds Advisory first reported a position in DGX in Q2 2013 and has held it in 23 quarters since. The position peaked at $789K in Q2 2017. 625 funds tracked by Wall St. Rank hold DGX as of Q4 2018.

  • Marshwinds Advisory held 7,100 shares of Quest Diagnostics worth $591K as of Q4 2018.
  • Marshwinds Advisory left its Quest Diagnostics share count unchanged in Q4 2018.
  • Quest Diagnostics made up 0.32% of Marshwinds Advisory's portfolio in Q4 2018, its #74 holding.
  • Marshwinds Advisory first reported a position in Quest Diagnostics in Q2 2013 and has held it in 23 quarters since.
  • Marshwinds Advisory's Quest Diagnostics position peaked at $789K in Q2 2017.
  • 625 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2018.

Based on Marshwinds Advisory's 13F filing for Q4 2018, filed 7 Jan 2019.